Effect of PPARγ inhibition on pulmonary endothelial cell gene expression: Gene profiling in pulmonary hypertension

Physiological Genomics

Volumn 40, Issue 1, 2009, Pages 48-60

  Tian, Jing ^a   Smith, Anita ^a   Nechtman, John ^a   Podolsky, Robert ^a   Aggarwal, Saurabh ^a   Snead, Connie ^a   Kumar, Sanjiv ^a   Elgaish, Manal ^a   Oishi, Peter ^c   Göerlach, Agnes ^b   Fratz, Sohrab ^b   Hess, John ^b   Catravas, John D ^a   Verin, Alexander D ^a   Fineman, Jeffrey R ^c   She, Jin Xiong ^a   Black, Stephen M ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cell signaling; Microarray; Peroxisome proliferator activated receptor

Indexed keywords

CAVEOLIN 1; FIBROBLAST GROWTH FACTOR 2; HYALURONAN MEDIATED MOTILITY RECEPTOR; MEMBRANE PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN EPAS1; UBIQUITIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; ZINC FINGER PROTEIN; 2 CHLORO 5 NITROBENZANILIDE; 2-CHLORO-5-NITROBENZANILIDE; ANILIDE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; COW; DOWN REGULATION; ENDOTHELIUM CELL; EXPRESSED SEQUENCE TAG; GENE EXPRESSION; GENE EXPRESSION PROFILING; LUNG ENDOTHELIUM; LUNG PARENCHYMA; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; ARTERY; CATTLE; CELL ADHESION; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG; LUNG GAS EXCHANGE; METABOLISM; PATHOLOGY; REPRODUCIBILITY; SHEEP;

OVIS;

ANILIDES; ANIMALS; ARTERIES; BLOOD-AIR BARRIER; CATTLE; CELL ADHESION; CELL CYCLE; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION, PULMONARY; LUNG; NEOVASCULARIZATION, PHYSIOLOGIC; PPAR GAMMA; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SHEEP; UBIQUITIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; ZINC FINGERS;

EID: 73649118195     PISSN: 10948341     EISSN: 15312267     Source Type: Journal    
DOI: 10.1152/physiolgenomics.00094.2009     Document Type: Article

References (59)

1. Ahanchi SS, Varu VN, Tsihlis ND, Martinez J, Pearce CG, Kapadia MR, Jiang Q, Saavedra JE, Keefer LK, Hrabie JA, Kibbe MR. Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome. Am J Physiol Heart Circ Physiol 295: H2388-H2398, 2008.
2. Ameshima S, Golpon H, Cool CD, Chan D, Vandivier RW, Gardai SJ, Wick M, Nemenoff RA, Geraci MW, Voelkel NF. Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res 92: 1162-1169, 2003.
3. Bar-Or C, Czosnek H, Koltai H. Cross-species microarray hybridizations: a developing tool for studying species diversity. Trends Genet 23: 200-207, 2007.
4. Bishop-Bailey D, Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J Biol Chem 274: 17042-17048, 1999.
5. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193, 2003.
6. Bruemmer D, Blaschke F, Law RE. New targets for PPARgamma in the vessel wall: implications for restenosis. Int J Obes (Lond) 29, Suppl 1: S26-S30, 2005.
7. Burg J, Krump-Konvalinkova V, Bittinger F, Kirkpatrick CJ. GMCSF expression by human lung microvascular endothelial cells: in vitro and in vivo findings. Am J Physiol Lung Cell Mol Physiol 283: L460-L467, 2002.
8. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1: 193-199, 1999.
9. Collins AR. Pleiotropic vascular effects of PPARgamma ligands. Drug News Perspect 16: 197-204, 2003.
10. Cool CD, Kennedy D, Voelkel NF, Tuder RM. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 28: 434-442, 1997.
11. Cool CD, Stewart JS, Werahera P, Miller GJ, Williams RL, Voelkel NF, Tuder RM. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 155: 411-419, 1999.
12. De Nigris F, Lerman LO, Napoli C. New insights in the transcriptional activity and coregulator molecules in the arterial wall. Int J Cardiol 86: 153-168, 2002.
13. Duan SZ, Usher MG, Mortensen RM. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ Res 102: 283-294, 2008.
14. Favier J, Kempf H, Corvol P, Gasc JM. Coexpression of endothelial PAS protein 1 with essential angiogenic factors suggests its involvement in human vascular development. Dev Dyn 222: 377-388, 2001.
15. Forman BM, Chen J, Evans RM. The peroxisome proliferator-activated receptors: ligands and activators. Ann NY Acad Sci 804: 266-275, 1996.
16. Genini D, Carbone GM, Catapano CV. Multiple interactions between peroxisome proliferators-activated receptors and the ubiquitin-proteasome system and implications for cancer pathogenesis. PPAR Res 2008: 195065, 2008.
17. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100: 57-70, 2000.
18. Hansmann G, Wagner RA, Schellong S, Perez VA, Urashima T, Wang L, Sheikh AY, Suen RS, Stewart DJ, Rabinovitch M. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation 115: 1275-1284, 2007.
19. Haworth SG. The pathology of pulmonary hypertension. Primary Pulmonary Hypertension: Executive Summary from the 2nd World Symposium Primary Pulmonary Hypertension. Évian-les-Bains, France, 1998.
20. Hihi AK, Michalik L, Wahli W. PPARs: transcriptional effectors of fatty acids and their derivatives. Cell Mol Life Sci 59: 790-798, 2002.
21. Hsu MH, Palmer CN, Song W, Griffin KJ, Johnson EF. A carboxyl-terminal extension of the zinc finger domain contributes to the specificity and polarity of peroxisome proliferator-activated receptor DNA binding. J Biol Chem 273: 27988-27997, 1998.
22. Hsueh WA, Jackson S, Law RE. Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care 24: 392-397, 2001.
23. Hsueh WA, Law RE. PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol 21: 1891-1895, 2001.
24. Joazeiro CA, Weissman AM. RING finger proteins: mediators of ubiquitin ligase activity. Cell 102: 549-552, 2000.
25. Kim EH, Surh YJ. The role of 15-deoxy-delta(12,14)-prostaglandin J(2), an endogenous ligand of peroxisome proliferator-activated receptor gamma, in tumor angiogenesis. Biochem Pharmacol 76: 1544-1553, 2008.
26. Kliewer SA, Willson TM. The nuclear receptor PPARgamma - bigger than fat. Curr Opin Genet Dev 8: 576-581, 1998.
27. Klug A. Zinc finger peptides for the regulation of gene expression. J Mol Biol 293: 215-218, 1999.
28. Lee MS, Kliewer SA, Provencal J, Wright PE, Evans RM. Structure of the retinoid X receptor alpha DNA binding domain: a helix required for homodimeric DNA binding. Science 260: 1117-1121, 1993.
29. Margeli A, Kouraklis G, Theocharis S. Peroxisome proliferator activated receptor-gamma (PPAR-gamma) ligands and angiogenesis. Angiogenesis 6: 165-169, 2003.
30. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 94: 1168-1178, 2004.
31. Marx N, Walcher D. Vascular effects of PPARgamma activators - from bench to bedside. Prog Lipid Res 46: 283-296, 2007.
32. Mirzapoiazova T, Kolosova I, Usatyuk PV, Natarajan V, Verin AD. Diverse effects of vascular endothelial growth factor on human pulmonary endothelial barrier and migration. Am J Physiol Lung Cell Mol Physiol 291: L718-L724, 2006.
33. Nicoli S, De Sena G, Presta M. Fibroblast growth factor 2-induced angiogenesis in zebrafish: the zebrafish yolk membrane (ZFYM) angiogenesis assay. J Cell Mol Med 2008.
34. Nisbet RE, Bland JM, Kleinhenz DJ, Mitchell PO, Walp ER, Sutliff RL, Hart CM. Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model. Am J Respir Cell Mol Biol 2009.
35. Nisbet RE, Sutliff RL, Hart CM. The role of peroxisome proliferator-activated receptors in pulmonary vascular disease. PPAR Res 2007: 18797, 2007.
36. Oishi PE, Wiseman DA, Sharma S, Kumar S, Hou Y, Datar SA, Azakie A, Johengen MJ, Harmon C, Fratz S, Fineman JR, Black SM. Progressive dysfunction of nitric oxide synthase in a lamb model of chronically increased pulmonary blood flow: a role for oxidative stress. Am J Physiol Lung Cell Mol Physiol 295: L756-L766, 2008.
37. Pearse DB, Shimoda LA, Verin AD, Bogatcheva N, Moon C, Ronnett GV, Welsh LE, Becker PM. Effect of cGMP on lung microvascular endothelial barrier dysfunction following hydrogen peroxide. Endothelium 10: 309-317, 2003.
38. Polikandriotis JA, Mazzella LJ, Rupnow HL, Hart CM. Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms. Arterioscler Thromb Vasc Biol 25: 1810-1816, 2005.
39. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 118: 2372-2379, 2008.
40. Reddy VM, Meyrick B, Wong J, Khoor A, Liddicoat JR, Hanley FL, Fineman JR. In utero placement of aortopulmonary shunts. A model of postnatal pulmonary hypertension with increased pulmonary blood flow in lambs. Circulation 92: 606-613, 1995.
41. Reinstein E, Ciechanover A. Narrative review: protein degradation and human diseases: the ubiquitin connection. Ann Intern Med 145: 676-684, 2006.
42. Rich S, Rabinovitch M. Diagnosis and treatment of secondary (noncategory 1) pulmonary hypertension. Circulation 118: 2190-2199, 2008.
43. Rios-Vazquez R, Marzoa-Rivas R, Gil-Ortega I, Kaski JC. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. Am J Cardiovasc Drugs 6: 231-242, 2006.
44. Sage J. Cyclin C makes an entry into the cell cycle. Dev Cell 6: 607-608, 2004.
45. Savani RC, Cao G, Pooler PM, Zaman A, Zhou Z, DeLisser HM. Differential involvement of the hyaluronan (HA) receptors CD44 and receptor for HA-mediated motility in endothelial cell function and angiogenesis. J Biol Chem 276: 36770-36778, 2001.
46. Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 8: 159-166, 1997.
47. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1302: 93-109, 1996.
48. Slevin M, Krupinski J, Gaffney J, Matou S, West D, Delisser H, Savani RC, Kumar S. Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways. Matrix Biol 26: 58-68, 2007.
49. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3, 2004.
50. Spiegelman BM. Peroxisome proliferator-activated receptor gamma: A key regulator of adipogenesis and systemic insulin sensitivity. Eur J Med Res 2: 457-464, 1997.
51. Stevens T. Molecular and cellular determinants of lung endothelial cell heterogeneity. Chest 128: 558S-564S, 2005.
52. Tomanek RJ, Hansen HK, Christensen LP. Temporally expressed PDGF and FGF-2 regulate embryonic coronary artery formation and growth. Arterioscler Thromb Vasc Biol 28: 1237-1243, 2008.
53. Touyz RM, Schiffrin EL. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascul Pharmacol 45: 19-28, 2006.
54. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144: 275-285, 1994.
55. Viallard JF, Lacombe F, Belloc F, Pellegrin JL, Reiffers J. [Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology]. Cancer Radiother 5: 109-129, 2001.
56. Wakino S, Law RE, Hsueh WA. Vascular protective effects by activation of nuclear receptor PPARgamma. J Diabetes Complications 16: 46-49, 2002.
57. Wang J, Maldonado MA. The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases. Cell Mol Immunol 3: 255-261, 2006.
58. Wedgwood S, Mitchell CJ, Fineman JR, Black SM. Developmental differences in the shear stress-induced expression of endothelial NO synthase: changing role of AP-1. Am J Physiol Lung Cell Mol Physiol 284: L650-L662, 2003.
59. Williams TM, Lisanti MP. The Caveolin genes: from cell biology to medicine. Ann Med 36: 584-595, 2004.